Pictorial Support in Person-centred Care for Children (PicPecc)
Launched by GÖTEBORG UNIVERSITY · Jun 14, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PicPecc trial is studying a new way to help children aged 5 to 17 years with cancer communicate about their symptoms during treatment with high-dose methotrexate. The researchers are testing a digital tool that uses pictures instead of words, making it easier for kids to express how they feel. This tool aims to improve communication between children, their families, and healthcare professionals, which is important for providing better care.
To participate in this study, children must be diagnosed with cancer and be able to understand a simple number scale to rate their symptoms. Their parents or guardians and healthcare workers involved in their care are also included. Participants will use the picture-based tool to share their experiences and feelings. The study will include interviews to gather feedback on how helpful the tool is and monitor children for signs of stress and pain through simple blood tests. The goal is to enhance care for young patients by ensuring their voices are heard.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children with cancer, 5-17 years
- • The children´s legal guardians
- • Healthcare professionals who take care of these children
- • The child needs to have a cognitive level of approximately five years (i.e., be able to understand a numeric rating scale (NRS)).
- Exclusion Criteria:
- • - Children 0-4 years
About Göteborg University
Göteborg University, a leading academic institution in Sweden, is committed to advancing healthcare through innovative research and clinical trials. With a strong focus on interdisciplinary collaboration, the university leverages its extensive expertise in various fields, including medicine, pharmacology, and social sciences, to address pressing health challenges. By sponsoring clinical trials, Göteborg University aims to contribute to the development of new therapies and improve patient outcomes, while adhering to the highest ethical standards and regulatory requirements. Their dedication to rigorous scientific inquiry and community engagement positions them as a pivotal player in the global health research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gothenburg, , Sweden
Patients applied
Trial Officials
Stefan Nilsson, PhD
Principal Investigator
Institute of Health and Care Sciences, University of Gothenburg, Sweden
Jonas Bergquist, Professor
Study Director
Dept of Chemistry Biomedical Centre, Uppsala University, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials